AI藥物研發公司Genesis Therapeutics近日宣佈，再次獲得英偉達（Nvidia）旗下風險投資部門NVentures的追加投資，具體金額未披露。此舉標誌着雙方合作的進一步深化，旨在加速Genesis的AI平臺GEMS(Genesis Exploration of Molecular Space)的開發，該平臺專注於利用物理AI進行結構驅動的藥物設計。源於斯坦福，深耕分子AIGenesis Therapeutics由Vijay Pande博士在斯坦福大學的實驗室衍生而來。聯合創始人Evan Feinberg博士在研究生期間與Pande共同發明並撰寫了多篇關於深度學習技術的關鍵論文，其中最引人注目的是Potential
["Hugging Face 獲得 2.35 億美元融資，估值 45 億美元","Genesis Therapeutics 獲得 2 億美元融資，致力於人工智能藥物設計","AI21 Labs 完成 1.55 億美元 C 輪融資，估值 14 億美元","Anthropic 獲得 1 億美元融資，與 SKT 合作構建定製大模型","Modular 獲得 1 億美元融資，致力於提供 AI 基礎設施"]
["加利福尼亞初創公司 Genesis Therapeutics 成功籌集 2 億美元資金。","此輪融資由 Andreessen Horowitz 和一家未透露身份的生命科學投資者共同領投。","Genesis 計劃利用資金推進其 AI 藥物項目的臨牀試驗，並擴大其在新領域的研究。"]
%20--%3e%3cdefs%3e%3cstyle%3e%20.st0%20{%20fill:%20%23061b40;%20}%20.st1%20{%20fill:%20%23306af1;%20}%20.st2%20{%20fill:%20%235ce5cf;%20}%20%3c/style%3e%3c/defs%3e%3cg%3e%3cpath%20class='st0'%20d='M55,10.5h9v3h-9v9h12V7.5h-12v3ZM64,19.5h-6v-3h6v3Z'/%3e%3cpolygon%20class='st0'%20points='69%2016.5%2078%2016.5%2078%2019.5%2069%2019.5%2069%2022.5%2081%2022.5%2081%2013.5%2072%2013.5%2072%2010.5%2081%2010.5%2081%207.5%2069%207.5%2069%2016.5'/%3e%3cpolygon%20class='st0'%20points='95%2010.5%2095%207.5%2083%207.5%2083%2022.5%2095%2022.5%2095%2019.5%2086%2019.5%2086%2016.5%2095%2016.5%2095%2013.5%2086%2013.5%2086%2010.5%2095%2010.5'/%3e%3cpath%20class='st0'%20d='M40,1.5v21h11.6l1.4-1.4v-7.6h0c0,0-1.4-1.5-1.4-1.5l1.4-1.4V2.9l-1.4-1.4h-11.6ZM50,19.5h-7v-6h7v6ZM50,10.5h-7v-6h7v6Z'/%3e%3c/g%3e%3cpath%20class='st1'%20d='M23.1,24L14.7,4.8l-4.9,11.2h3.8l-1.8,4H3.3L12.1,0H2C.9,0,0,.9,0,2v20c0,1.1.9,2,2,2h21.1Z'/%3e%3cpath%20class='st2'%20d='M34,0h-16.8l10.6,24h6.2c1.1,0,2-.9,2-2V2C36,.9,35.1,0,34,0ZM32.5,20h-4V4h4v16Z'/%3e%3c/svg%3e)
